[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pelvic-pain\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pelvic-pain":26},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,35,0,25,[9,41,70,114,158,187,216,244,271,306,328,354,379,410,434,465,491,518,542,567,589,621,631,656,680],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100053243","endometriosis-pain-100053243",false,"NCT06101303","Endometriosis Pain","The Mechanisms Underlying Endometriosis Pain","Inclusion criteria:\n\n* Patients with pelvic pain with and without endometriosis scheduled for an operative laparoscopic surgery for endometriosis diagnosis and\u002For treatment\n* Age 12-45\n* Females\n\nExclusion criteria:\n\n* Pregnancy\n* Planned hysterectomy or oophorectomy\n* Co-occurring vaginismus and\u002For vulvodynia\n* For patients aged 12-17 not having a parent\u002Flegal guardian willing to sign the consent and answer surveys about their child's health","FEMALE","12 Years","45 Years",{"count":21,"type":22},120,"ESTIMATED","OBSERVATIONAL","Aim 1. To determine the factors contributing to pain in patients with chronic pelvic pain with and without endometriosis Aim 2. To determine the changes following endometriosis lesion removal surgery in pain and sex hormone levels.\n\nAim 3. To identify factors predicting clinical pain reduction after lesion removal surgery.\n\nAdditional exploratory aims might compare subgroups of patients such as patients with vs. without endometriosis, with vs. without additional chronic pain syndromes, and with vs. without hormonal treatment. In addition, the role of lesion-specific immune signatures and psychological factors on pain will be explored.\n\nPatients with pelvic pain potentially due to endometriosis will complete questionnaires including social, health, behavioral, and psychological questionnaires. Patients will also complete a 2.5 hours study visit of psychophysical assessments of thermal and pressure stimuli. In addition, blood, urine, and saliva samples will be collected for hormonal, immune, and genetic analyses. Additional samples might be collected and stored for future analyses. For some participants, these procedures will be completed several times, including before the surgery as well as 3 months, 6 months and 1 year after surgery. After the surgery, surveys assessing pain and other symptoms will be sent every week on the first month and then monthly for 1 year. In addition, during the surgery, biopsies will be collected and analyzed to determine hormonal, immune and genetic factors.\n\nFor adolescents, a parent\u002Flegal guardian will be asked to assist in completing some of the health-related surveys (i.e., physical developmental survey, health survey, migraine history survey).",[26,27],"Pelvic Pain","Endometriosis","RECRUITING","2026-07-10",{"date":31,"type":32},"2026-07-13","ACTUAL",{"date":34,"type":32},"2023-09-29",{"date":36,"type":22},"2029-09-01",{"name":38,"class":39},"Washington University School of Medicine","OTHER",1,{"id":42,"slug":43,"hasResults":12,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":12,"sex":17,"minAge":49,"maxAge":19,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":69},"100589500","effect-of-alcohol-sclerotherapy-on-pelvic-pain-and-quality-of-life-in-women-with-ovarian-endometriosis-100589500","NCT06955221","Effect of Alcohol Sclerotherapy on Pelvic Pain and Quality of Life in Women With Ovarian Endometriosis","Effect of US-guided Alcohol Sclerotherapy for Endometriomas on Pelvic Pain and Quality of Life","ESCOMA","Inclusion Criteria:\n\n* Female sex\n* Age ≥18 and ≤45 years\n* Ultrasound suspicion of unilocular endometrioma or with a thin septum less than 3 mm\n* Size between 30-100 mm, persistent for at least 3-6 months since diagnosis\n* Ca125 marker \\\u003C300 UI\u002FmL and HE4 \\\u003C 70 pM\n* Signed informed consent\n\nExclusion Criteria:\n\n* Age \\\u003C18 or \\>45 years\n* History of ovarian or uterine cancer\n* Endometrioma size \\\u003C30 mm or \\>100 mm\n* Indication for surgical treatment of the endometrioma due to suspected severe extra-ovarian endometriosis or any other cause\n* Ultrasound suspicion of dermoid cysts, anechoic cysts, or cysts with high risk of malignancy\n* Ca125 \\>300 UI\u002FmL\n* HE4 \\>70 pM\n* Pregnant women\n* Patients who do not wish to participate in the study or who are mentally incapacitated","18 Years",{"count":51,"type":22},288,"INTERVENTIONAL",[54],"NA","The goal of this clinical trial is to evaluate whether ultrasound-guided alcohol sclerotherapy can improve pelvic pain and quality of life in women aged 18 to 45 diagnosed with ovarian endometriomas, compared to expectant management.\n\nThe main questions it aims to answer are:\n\n1. \\- Does sclerotherapy significantly reduce pelvic pain compared to expectant management?\n2. \\- Does sclerotherapy improve quality of life as measured by the EHP-5 score?\n\nResearchers will compare the sclerotherapy group to the expectant management group to determine whether the intervention leads to greater improvement in pain and quality of life.\n\nParticipants will:\n\n* Be randomly assigned to one of two groups: (1) Sclerotherapy group: undergo ultrasound-guided puncture and alcohol sclerotherapy; (2) Control group: expectant management\n* Complete quality of life and pain assessments at baseline and after 6 months\n* Provide blood and urine samples for biomarker analysis (e.g., cortisol, IL-6, hsCRP, catecholamines)\n* Undergo ovarian reserve assessments (AMH, antral follicle count)\n* Be followed for adverse events, recurrence, fertility outcomes, and treatment-related costs\n\nThe study will follow an intention-to-treat and per-protocol analysis approach.",[57,58,59,26],"Endometrioma","Ultrasound Therapy; Complications","Quality of Life","2026-06-27",{"date":62,"type":32},"2026-07-01",{"date":64,"type":32},"2025-01-01",{"date":66,"type":22},"2027-12-31",{"name":68,"class":39},"Hospital Universitari de Bellvitge",28,{"id":71,"slug":72,"hasResults":12,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":78,"sex":17,"minAge":49,"maxAge":79,"enrollmentInfo":80,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":82,"conditions":83,"keywords":89,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":40},"100645235","crest-samphire-guided-care-program-on-wellbeing-work-productivity-and-quality-of-life-100645235","NCT07679074","CREST: Samphire Guided Care Program on Wellbeing, Work Productivity, and Quality of Life","A 12-Week Prospective Cohort Study Evaluating the Efficacy of the Samphire Guided Care Program on Wellbeing, Work Productivity, and Quality of Life in Individuals With Menstrual and Pelvic Health Conditions","CREST","Inclusion Criteria:\n\n* Self-identified female, aged 18-65 years at the time of enrollment\n* Basic English literacy\n* Able and willing to provide informed consent electronically\n* Residing in the United States\n* Reporting mood or cognitive symptoms associated with menstruation, perimenopause, or menopause (must endorse a minimum of three of the following: irritability, emotional dysregulation, brain fog, fatigue, reduced concentration, sleep disruption, or low mood)\n* Symptoms present for at least 3 months and sufficiently severe to interfere with daily functioning, work performance, quality of life, or interpersonal relationships\n* Currently in full-time employment with medical benefits as part of compensation package\n* Access to a smartphone with internet access compatible with the Samphire mobile application\n* Able to safely operate the study device in the home environment\n* Willing to complete baseline, mid-program, and end-of-program questionnaires and engage with the 12-week guided care program\n\nExclusion Criteria:\n\n* Pregnancy, breastfeeding, or actively planning pregnancy during the study period\n* History of epilepsy or seizure disorder\n* Severe or unstable neurological disease that, in the opinion of the study team, may increase risk or interfere with participation\n* Implanted electronic or metal devices in the head, neck, or brain region contraindicated for tDCS use\n* Active scalp lesions, open wounds, or dermatologic conditions at electrode sites that may interfere with safe device use\n* Current diagnosis of schizophrenia, bipolar disorder, or other severe psychiatric condition that would make participation inappropriate, as determined by screening\n* Active suicidal ideation, recent suicidal behavior, or clinically significant self-injurious behavior, as determined by participant self-report during screening\n* Inability to provide informed consent or safely use the device in the home environment\n* Current participation in another interventional neurotechnology or drug study",true,"65 Years",{"count":81,"type":22},50,"This study evaluates the feasibility and efficacy of the Samphire Guided Care (SGC) program\n\n* a 12-week structured digital health program combining clinician-led onboarding, at-home neuromodulation using the Lutea tDCS device, neuromodulation coach support, and app-based symptom tracking - on work productivity, employee wellbeing, and quality of life in individuals experiencing mood and cognitive symptoms associated with menstruation, perimenopause, or menopause.",[84,85,86,27,87,88,26],"Premenstrual Syndrome","Premenstrual Dysphoric Disorder","Dysmenorrhea","Perimenopause","Menopause",[90,91,92,93,94,95,96,97,98,99,100,101,102,103,104],"tDCS","neuromodulation","hormonal health","menstrual symptoms","perimenopause","menopause","PMDD","PMS","work productivity","brain fog","mood","cognitive function","digital health","decentralized clinical trial","guided care","2026-06-25",{"date":62,"type":32},{"date":108,"type":32},"2026-06-01",{"date":110,"type":22},"2027-03-01",{"name":112,"class":113},"Samphire Group, Inc.","INDUSTRY",{"id":115,"slug":116,"hasResults":12,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":4,"eligibilityCriteria":120,"healthyVolunteers":12,"sex":17,"minAge":49,"maxAge":4,"enrollmentInfo":121,"targetDuration":4,"studyType":52,"phases":122,"briefSummary":123,"conditions":124,"keywords":128,"overallStatus":148,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":40},"100641011","measuring-pelvic-floor-muscle-fitness-before-and-after-treatment-100641011","NCT07605598","Measuring Pelvic Floor Muscle Fitness Before and After Treatment","Quantitative Assessment of Pelvic Floor Muscle Fitness in Myofascial Pelvic Pain Before and After Myofascially-Directed Therapies","Inclusion Criteria:\n\nWomen over 18 years of age\n\nPelvic Pain for more than 3 months\n\nReport an average daily pain intensity score of at least 4 on a 0 to 10 scale\n\nPalpable trigger\u002Ftender points in internal pelvic floor muscles on standardized myofascial pelvic floor exam\n\nWilling to refrain from new clinical treatment that may affect pain during the study period\n\nExclusion Criteria\n\nInability to participate in clinic visits\n\nPrior invasive pelvic procedures for pain (e.g., prior pelvic surgery, sacral neuromodulation, intradetrusor Botox®) in the past 6 months\n\nActive UTI or vaginal infection\n\nPregnancy or childbirth in the past 12 months, currently planning a pregnancy\n\nIllicit Drug addiction\u002Fregular use of controlled substances (including marijuana use in the past 2 weeks or during the study period)\n\nPelvic floor physical therapy in the past 3 months\n\nMalignancy or other serious medical condition (e.g., poorly controlled diabetes \\[HgA1c \\> 8\\], chronic renal disease \\[GFR \\\u003C30\\], neurologic or rheumatic disease)\n\nDiagnosed with an alternate cause of pelvic pain (e.g., ulcerative interstitial cystitis, vestibulodynia, vulvar dermatoses, dysmenorrhea)\n\nUrinary retention with a PVR \\>150 mL\n\nGreater than stage 3 pelvic organ prolapse\n\nIndwelling vaginal devices (e.g., pessary, contraceptive ring. Not including Mirena IUD) that cannot be removed for the study\n\nInability to sign an informed consent, fill out questionnaires, or complete study interviews",{"count":21,"type":22},[54],"This study is being done to better understand and improve treatment for myofascial pelvic pain, a common cause of long-lasting pelvic pain in women. Myofascial pelvic pain is related to tight or dysfunctional pelvic floor muscles and can cause pain as well as bladder, bowel, and sexual problems. Current clinical evaluations mostly rely on physical examination and patient-reported symptoms and do not fully measure how the pelvic floor muscles are functioning.\n\nThe purpose of this study is to measure pelvic floor muscle function using a noninvasive imaging method called near-infrared spectroscopy, or NIRS. This method measures changes in muscle blood flow and oxygen levels during muscle contraction and relaxation. The study will examine whether pelvic floor muscle function improves after different treatments and whether these physiologic changes are associated with improvements in pain and symptoms.\n\nThe study will enroll 120 adult women who have had pelvic pain for at least three months and have pelvic floor muscle tenderness on examination. Participants will be randomly assigned to one of three groups: education with relaxation exercises, pelvic floor physical therapy focused on myofascial release, or vaginal medication used to help relax pelvic floor muscles.\n\nParticipants will take part in four study visits over a six-month period. During these visits, they will complete questionnaires about pain and pelvic symptoms, undergo pelvic floor examinations, and have pelvic floor muscle imaging using the NIRS device while performing brief muscle contractions and relaxations. Some visits will also include collection of blood, urine, and vaginal samples to measure inflammation.\n\nThe information gained from this study may help improve the diagnosis and treatment of myofascial pelvic pain by providing objective measures of pelvic floor muscle function and identifying which treatments are most effective for different patients.",[125,26,126,127],"Myofacial Pain","Myofascial Pelvic Pain","Chronic Pelvic Pain",[129,130,131,132,133,134,135,136,137,138,139,140,141,142,143,144,145,146,147],"myofascial pelvic pain","chronic pelvic pain","pelvic floor muscle dysfunction","pelvic floor myalgia","pelvic floor hypertonicity","Near-infrared spectroscopy","NIRS imaging","Pelvic floor muscle oxygenation","Pelvic floor muscle blood flow","Pelvic floor muscle fitness","Pelvic floor physical therapy","Myofascial release therapy","Pelvic floor relaxation therapy","Intravaginal diazepam","Intravaginal baclofen","Pelvic floor muscle relaxation medication","Women's pelvic pain","Noninvasive pelvic floor assessment","Pelvic floor imaging","NOT_YET_RECRUITING","2026-05-21",{"date":151,"type":32},"2026-05-26",{"date":153,"type":22},"2026-09-01",{"date":155,"type":22},"2029-07-01",{"name":157,"class":39},"University of California, Los Angeles",{"id":159,"slug":160,"hasResults":12,"nctId":161,"briefTitle":162,"officialTitle":163,"acronym":164,"eligibilityCriteria":165,"healthyVolunteers":12,"sex":17,"minAge":166,"maxAge":167,"enrollmentInfo":168,"targetDuration":4,"studyType":52,"phases":170,"briefSummary":172,"conditions":173,"keywords":174,"overallStatus":148,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":40},"100637160","phase-4-comparing-pain-improvement-for-intravenous-versus-oral-acetaminophen-in-acute-pelvic-pain-100637160","NCT07595302","Comparing Pain Improvement for Intravenous Versus Oral Acetaminophen in Acute Pelvic Pain","Comparing Pain Improvement for Intravenous Versus Oral Acetaminophen in Acute Pelvic Pain: A Randomized, Double-Blind, Double-Dummy Controlled Trial (PIVOTAL Trial)","PIVOTAL","Inclusion Criteria:\n\n* Female sex at birth\n* Presentation to the Emergency Department (ED) with pelvic pain\n* Baseline numeric pain score (NRS) ≥4\n* Ability to provide informed consent in English or Spanish\n\nExclusion Criteria:\n\n* Receipt of any analgesic medication within 2 hours or acetaminophen within 6 hours\n* Known allergy or intolerance to acetaminophen","16 Years","50 Years",{"count":169,"type":22},140,[171],"PHASE4","The investigator team proposes a randomized, double-blind, double-dummy comparative effectiveness trial conducted in two urban emergency departments (EDs) in the Bronx, New York. This study is designed to determine the relative efficacy of IV acetaminophen compared to PO acetaminophen in treating pelvic pain. This design focuses on the early onset of action and short-term efficacy, which may better capture potential differences between IV and PO acetaminophen in the acute ED setting.",[26],[175,176,177],"pregnancy","acetaminophen","randomized controlled trial","2026-05-18",{"date":180,"type":32},"2026-05-20",{"date":182,"type":22},"2026-07-30",{"date":184,"type":22},"2027-06-30",{"name":186,"class":39},"Montefiore Medical Center",{"id":188,"slug":189,"hasResults":12,"nctId":190,"briefTitle":191,"officialTitle":192,"acronym":193,"eligibilityCriteria":194,"healthyVolunteers":12,"sex":195,"minAge":49,"maxAge":4,"enrollmentInfo":196,"targetDuration":4,"studyType":52,"phases":198,"briefSummary":199,"conditions":200,"keywords":203,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":206,"lastUpdatePostDateStruct":207,"startDateStruct":209,"completionDateStruct":211,"leadSponsor":213,"locationsCount":215},"100486336","comparative-effectiveness-of-online-8-session-cbt-vs-1-session-empowered-relief-for-chronic-pain---the-progress-study-100486336","NCT05612750","Comparative Effectiveness of Online 8-session CBT vs. 1-Session Empowered Relief for Chronic Pain - The PROGRESS Study","Comparative Effectiveness of Online Cognitive Behavioral Therapy vs. An Online Single-Session Pain Relief Skills Class for Chronic Pain - The PROGRESS Study","PROGRESS","Inclusion Criteria:\n\n1. At least 18 years of age or older of either sex (and all genders).\n2. Chronic pain (pain that occurs on at least half of the days of 3 months or more).\n3. Past-month average pain intensity score of at least 3\u002F10.\n4. Ability to adhere to and complete study protocols.\n\nExclusion Criteria:\n\n1. Inability to provide informed consent.\n2. Cognitive impairment, non-English speaking, or psychological factors that would preclude comprehension of material and\u002For full participation in the study including group treatment.\n3. Active suicidality documented in medical records.\n4. Study staff may exclude individuals with a known history of disruptive behavior to minimize contamination of the learning environment for an entire treatment cohort.\n5. Receipt of either study treatment in the past 3 months.","ALL",{"count":197,"type":22},1650,[54],"The purpose of this study is to conduct a pragmatic clinical trial comparing the effectiveness of: (1) 8-week cognitive behavioral therapy for chronic pain (pain-CBT; sixteen hours total treatment time); and (2) a 1-session pain relief skills intervention for chronic pain (Empowered Relief; two hours total treatment time).",[201,202,26],"Pain, Chronic","Lupus",[204,202,26,205],"Young adult","Behavioral Health","2026-05-07",{"date":208,"type":32},"2026-05-11",{"date":210,"type":32},"2023-01-01",{"date":212,"type":22},"2029-05-01",{"name":214,"class":39},"Stanford University",5,{"id":217,"slug":218,"hasResults":12,"nctId":219,"briefTitle":220,"officialTitle":221,"acronym":4,"eligibilityCriteria":222,"healthyVolunteers":12,"sex":17,"minAge":49,"maxAge":223,"enrollmentInfo":224,"targetDuration":4,"studyType":52,"phases":226,"briefSummary":227,"conditions":228,"keywords":231,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":236,"startDateStruct":238,"completionDateStruct":240,"leadSponsor":242,"locationsCount":40},"100623076","high-intensity-interval-training-and-menstrual-health-experience-in-primary-dysmenorrhea-100623076","NCT07391930","High-Intensity Interval Training and Menstrual Health Experience in Primary Dysmenorrhea.","Efficacy of a High-Intensity Interval Training Program and Analysis of Menstrual Health Experience in Women With Primary Dysmenorrhea: A Mixed-Methods Randomized Controlled Trial.","Inclusion Criteria:\n\n* nulliparous\n* primary dysmenorrhea\n* body mass index between 18 and 30\n* menstrual pain \\>5 according to the Numeric Pain Scale\n* exercise \\>45 minutes\u002Fweek\n* understand Spanish and can freely read and sign the informed consent form\n\nExclusion Criteria:\n\n* amenorrhea or cycles \\>35 days\n* secondary dysmenorrhea\n* pelvic or abdominal surgical intervention\n* use of hormonal drugs\n* diagnosed with fibromyalgia, muscoloskeletal injuries or medical comorbidities that prevent them from performing intense exercise\n* receiving physiotherapy for pelvic floor disorders\n* intense exercise \\>75 minutes\u002Fweek","40 Years",{"count":225,"type":22},60,[54],"The goal of this study is to evaluate whether a 12-week online supervised high-intensity interval training program can reduce menstrual pain and improve quality of life in women with primary dysmenorrhea. Participants will be divided into two groups: one receiving an educational workshop and the HIIT program, and a control group receiving only the workshop. Additionally, the study seeks to understand the personal experience of these women through weekly health diaries, exploring how the intervention affects their relationship with their bodies and their menstruation. The ultimate goal is to offer new, non-pharmacological evidence-based tools for managing menstrual pain.",[229,230,26],"Dysmenorrhea Primary","Menstrual Pain",[232,59,233,234],"High- Intensity Interval Training","Menstrual Health","Therapeutic Exercise","2026-04-19",{"date":237,"type":32},"2026-04-21",{"date":239,"type":32},"2026-02-18",{"date":241,"type":22},"2029-06",{"name":243,"class":39},"University of Alcala",{"id":245,"slug":246,"hasResults":12,"nctId":247,"briefTitle":248,"officialTitle":248,"acronym":4,"eligibilityCriteria":249,"healthyVolunteers":12,"sex":17,"minAge":250,"maxAge":79,"enrollmentInfo":251,"targetDuration":4,"studyType":52,"phases":253,"briefSummary":254,"conditions":255,"keywords":258,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":261,"lastUpdatePostDateStruct":262,"startDateStruct":264,"completionDateStruct":266,"leadSponsor":268,"locationsCount":40},"100545950","acupuncture-for-chronic-pelvic-pain-100545950","NCT06388590","Acupuncture for Chronic Pelvic Pain","\\*\\*Patients must be able to get care at Nellis Air Force Base (a military installation) in order to participate in this study\\*\\*\n\nInclusion Criteria:\n\n* Active Duty and DoD Female Beneficiaries (i.e. former military, spouse, dependent) aged 21-65 with chronic pelvic pain\n* Have negative laparoscopic findings for endometriosis\n\nExclusion Criteria:\n\n* Severe mental health disorders to include any disorder with psychotic features (e.g schizophrenia, bipolar, schizoaffective disorder)\n* Pelvic pain as a result of severe physical trauma (excluding sexual assault) such as traumatic childbirth, pelvic fractures or any other trauma as determined by the PI or AI.\n* Pregnancy","21 Years",{"count":252,"type":22},64,[54],"The objective of this study is to determine if alternative pain management strategies, namely acupuncture, may help reduce intensity of female pelvic pain compared to other pain control modalities. This research study will focus specifically on the Dragon's protocol of acupuncture which will seek to alleviate chronic non-endometriosis pelvic pain for women both with and without a history of sexual assault.\n\nThis study may support evidence for an inexpensive alternative means of treatment for patients with or without traumatic sexual history and chronic pelvic pain.",[26,256,257],"Acupuncture","Gynecology",[259,260],"integrative medicine","acupuncture","2026-04-09",{"date":263,"type":32},"2026-04-14",{"date":265,"type":32},"2024-12-01",{"date":267,"type":22},"2026-10",{"name":269,"class":270},"David Moss","FED",{"id":272,"slug":273,"hasResults":12,"nctId":274,"briefTitle":275,"officialTitle":275,"acronym":276,"eligibilityCriteria":277,"healthyVolunteers":12,"sex":17,"minAge":278,"maxAge":279,"enrollmentInfo":280,"targetDuration":4,"studyType":52,"phases":281,"briefSummary":282,"conditions":283,"keywords":288,"overallStatus":148,"whyStopped":4,"lastUpdateSubmitDate":297,"lastUpdatePostDateStruct":298,"startDateStruct":300,"completionDateStruct":302,"leadSponsor":304,"locationsCount":40},"100631514","transmucosal-uterosacral-electrical-stimulation-for-pelvic-pain-relief-100631514","NCT07501676","Transmucosal Uterosacral Electrical Stimulation for Pelvic Pain Relief","TUNES","Inclusion Criteria:\n\n* Female, 28-52 years of age\n* Scheduled to undergo uterine fibroid embolization (UFE) at Weill Cornell Medicine\n* Able to provide informed consent\n* Willing to comply with all study procedures and follow-up\n* Fluent in English (for completion of study assessments)\n\nExclusion Criteria:\n\n* Known or suspected pregnancy\n* Active pelvic infection\n* History of pelvic inflammatory disease within the past 6 months\n* Implanted electrical device (e.g., pacemaker, neurostimulator)\n* Current use of opioid pain medication prior to procedure\n* History of chronic pelvic pain not related to fibroids\n* Known allergy or sensitivity to medical-grade silicone\n* Participation in another interventional study within 30 days","28 Years","52 Years",{"count":225,"type":22},[54],"This study will test whether gentle electrical stimulation to nerves near the uterus can reduce pelvic pain after uterine fibroid embolization. The investigators hypothesize that participants receiving active TUNES stimulation will experience lower pain levels and improved early recovery compared to those receiving sham stimulation or standard care.",[284,285,286,26,287],"Postoperative Pain After Uterine Fibroid Embolization","Uterine Fibroids (UF)","Uterine Fibroids","Pain Management",[289,276,290,291,292,293,294,295,296],"Transmucosal Uterosacral Electrical Stimulation","Uterine Fibroid Embolization","UFE","Post-UFE Pain","Electrical Stimulation Therapy","Pelvic Pain Relief","Noninvasive Neuromodulation","Weill Cornell Medicine","2026-03-24",{"date":299,"type":32},"2026-03-30",{"date":301,"type":22},"2026-04-01",{"date":303,"type":22},"2026-09-30",{"name":305,"class":39},"Weill Medical College of Cornell University",{"id":307,"slug":308,"hasResults":12,"nctId":309,"briefTitle":310,"officialTitle":311,"acronym":4,"eligibilityCriteria":312,"healthyVolunteers":12,"sex":17,"minAge":49,"maxAge":4,"enrollmentInfo":313,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":315,"conditions":316,"keywords":318,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":320,"lastUpdatePostDateStruct":321,"startDateStruct":323,"completionDateStruct":325,"leadSponsor":326,"locationsCount":40},"100346724","quantify-the-degree-of-pain-relief-of-pelvic-congestion-syndrome-following-gonadal-vein-embolization-100346724","NCT03794466","Quantify the Degree of Pain Relief of Pelvic Congestion Syndrome Following Gonadal Vein Embolization","Quantification of Pain Relief With Gonadal Vein Embolization for Pelvic Congestion Syndrome","Inclusion Criteria:\n\n* Female patients 18 years of age or older\n* Meet the clinical and imaging criteria for the diagnosis of PCS and have no contraindications to coil embolization of the gonadal veins.\n* Patients who are treated with coil embolization of the gonadal veins in the Interventional Radiology division between October 1, 2018 to October 1, 2019.\n\nExclusion Criteria:\n\n* Patients less than 18 years of age.\n* Patients who are found to have an underlying cause of pelvic congestion syndrome unrelated to venous congestion and insufficiency. This includes, but is not limited to, nutcracker syndrome, or a mass resulting in extrinsic compression of the gonadal veins.\n* Patients who have received prior surgical therapy for PCS, including bilateral salpingo-oophorectomy (TAH-BSO), gonadal vein resection, or gonadal vein ligation.",{"count":314,"type":22},30,"The primary objective is to quantify the degree of pain relief in patients undergoing gonadal vein embolization with coils as well as identify clinical or imaging factors that are predictive of a positive response to treatment, or poor response to treatment.",[317,26],"Pelvic Congestive Syndrome",[319],"gonadal vein embolization","2026-03-18",{"date":322,"type":32},"2026-03-23",{"date":324,"type":32},"2019-05-10",{"date":66,"type":22},{"name":327,"class":39},"University of Kansas Medical Center",{"id":329,"slug":330,"hasResults":12,"nctId":331,"briefTitle":332,"officialTitle":333,"acronym":334,"eligibilityCriteria":335,"healthyVolunteers":78,"sex":17,"minAge":49,"maxAge":336,"enrollmentInfo":337,"targetDuration":4,"studyType":52,"phases":339,"briefSummary":340,"conditions":341,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":345,"lastUpdatePostDateStruct":346,"startDateStruct":348,"completionDateStruct":350,"leadSponsor":352,"locationsCount":353},"100528998","trial-of-ovarian-vein-and-pelvic-vein-embolization-in-women-with-chronic-pelvic-pain-and-pelvic-varices-100528998","NCT06168058","Trial of Ovarian Vein and Pelvic Vein Embolization in Women With Chronic Pelvic Pain and Pelvic Varices","Randomized Controlled, Single-Blinded, Parallel-Group Trial of Ovarian Vein and Pelvic Vein Embolization in Women With Chronic Pelvic Pain and Pelvic Varices (EMBOLIZE) Trial","EMBOLIZE","Inclusion Criteria:\n\n1. Presence of venous origin chronic pelvic pain for greater than 6 months (VAS ≥7 as determined by 4 consecutive weeks of baseline self-assessments) despite non-vascular therapy as delineated by the following criteria:\n\n   * Pain exacerbated by walking, standing or lifting\n   * Symptoms are at least partially alleviated by lying down\n   * Prolonged post-coital ache\n   * Absence of non-venous origin CPP as determined by Gynecology examination\n2. Symptoms-Varices-Pathophysiology Classification18 including of one of the following:\n\n   •S2V2PBGV,R,NT, S2V2PRGV,R,NT , S2V2PLGV,R,NT, with or without S2V2 PBIIV,R,NT, S2V2 PLIIV,R,NT, S2V2 PRIIV,R,NT\n3. CT, TAUS and diagnostic venography (if needed) imaging review for pelvic venous imaging factors\n\n   * Left or right ovarian vein diameter greater than or equal to 6 mm as documented by TAUS or CT\n   * Presence of intrabdominal\u002Fpelvic varices as documented by TAUS or CT (≥1 veins, \\>5 mm diameter)\n   * Presence of venous reflux in ovarian and\u002For internal iliac veins without evidence of hemodynamically significant stenosis\n\nExclusion Criteria:\n\n* Female \\\u003C18 years of age\n* Pregnancy (positive pregnancy test)\n* Female subject who plans to become pregnant during study period\n* Female subject who is actively breastfeeding\n* Patient who is post-menopausal or anovulatory with hormone suppression\n* History of prior hysterectomy\n* Prior ovarian vein embolization or ovarian vein ligation\n* Inability to tolerate endovascular procedure due to acute illness or general health\n* Planned simultaneous treatment with nerve blocks during the duration of the study\n* Laparoscopy or planned surgical intervention during the duration of the study\n* Known allergy to sclerosant, coil, stent or catheter components including nickel allergy\n* Any iliac vein stenosis determined identified by the investigator on pelvic DUS, CT venogram, and\u002For Catheter Venography and deemed significant for exclusion by study patient review committee.\n* Any renal vein stenosis with resultant renal hilar varices\u002Fcollaterals and lumbar collaterals identified by the investigator on pelvic DUS, CT venogram, and\u002For Diagnostic Venography and deemed significant for exclusion by study patient review committee.\n* Presence of isolated extra-pelvic vulvar and\u002For lower extremity varices without intrabdominal pelvic varices. Primary S3 categorization study exclusion.\n* Serious medical conditions that might preclude full participation in the study to the desired endpoint (e.g., uncontrolled diabetes, malignancy, COPD, MI, CHF, etc.)\n* Severe allergy to iodinated or gadolinium-based contrast refractory to steroid premedication\n* Severe renal impairment (on chronic dialysis or estimated GFR \\\u003C30 mL\u002Fmin)\n* Hemoglobin \\\u003C8.0 g\u002FdL, uncorrectable INR \\>3.0 or platelet count \\\u003C75,000\u002Fmicroliter\n* Inability to provide informed consent or to comply with study assessments\n* Post thrombotic IVC, iliac or ovarian vein changes","75 Years",{"count":338,"type":22},40,[54],"The purpose of this study is to see if a randomized controlled trial of ovarian vein and pelvic vein embolization versus venography alone could determine outcomes for women with chronic pelvic pain and pelvic varicose veins.\n\nThe data gathered will assist in addressing changes in quality of life in patients who have ovarian\u002Fpelvic vein embolization versus no embolization.",[342,26,343,317,344],"Chronic Pelvic Pain Syndrome","Pelvic Varices","Pelvic Pain Syndrome","2026-03-11",{"date":347,"type":32},"2026-03-13",{"date":349,"type":32},"2025-08-07",{"date":351,"type":22},"2027-06",{"name":305,"class":39},3,{"id":355,"slug":356,"hasResults":12,"nctId":357,"briefTitle":358,"officialTitle":358,"acronym":4,"eligibilityCriteria":359,"healthyVolunteers":12,"sex":17,"minAge":49,"maxAge":4,"enrollmentInfo":360,"targetDuration":4,"studyType":52,"phases":362,"briefSummary":363,"conditions":364,"keywords":368,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":371,"lastUpdatePostDateStruct":372,"startDateStruct":374,"completionDateStruct":376,"leadSponsor":377,"locationsCount":353},"100520670","pre-rehabilitation-for-female-patients-undergoing-pelvic-radiotherapy-100520670","NCT06059586","Pre-Rehabilitation for Female Patients Undergoing Pelvic Radiotherapy","Inclusion Criteria:\n\n1. Female\n2. ≥ 18 years old at the time of informed consent\n3. Ability to provide written informed consent and HIPAA authorization\n4. Primary diagnosis of cervical, vaginal, vulvar, uterine, or anal cancer\n5. Candidate for curative pelvic radiation with external beam, with or without brachytherapy, per radiation oncologist's discretion\n\nNotes:\n\n* Can have prior and\u002For current modalities of treatment to address diagnosis including surgery and chemotherapy\n* Can receive radiation at any facility provided patient is able to perform Physical Therapy visits at IUH North\u002FSchwarz Cancer Center\n\nExclusion Criteria:\n\n1. Major medical illnesses or psychiatric impairments, which in the investigator's opinion will prevent administration or completion of the protocol therapy and\u002For interfere with follow-up.\n2. Not a candidate for curative radiation therapy per radiation oncologist's discretion\n3. Prior radiation therapy to the pelvis\n4. Women who are pregnant or nursing",{"count":361,"type":22},20,[54],"The purpose of this study is to examine the feasibility of adding pre-rehabilitation pelvic health physical therapy to standard of care radiation therapy treatment plan for female patients who have been diagnosed with cervical, vaginal, vulvar, uterine, or anal cancer and are a candidate for curative pelvic radiation with external beam. Participants will receive education on using a vaginal dilator for use during treatment and complete questionnaires looking at pain and sexual function.",[365,26,366,367],"Dyspareunia","Sexual Dysfunction","Radiation Toxicity",[369,370],"vaginal dilator","pelvic health physical therapy","2026-02-25",{"date":373,"type":32},"2026-02-27",{"date":375,"type":32},"2024-01-16",{"date":351,"type":22},{"name":378,"class":39},"Indiana University",{"id":380,"slug":381,"hasResults":12,"nctId":382,"briefTitle":383,"officialTitle":383,"acronym":384,"eligibilityCriteria":385,"healthyVolunteers":12,"sex":17,"minAge":386,"maxAge":387,"enrollmentInfo":388,"targetDuration":4,"studyType":52,"phases":390,"briefSummary":392,"conditions":393,"keywords":394,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":239,"lastUpdatePostDateStruct":402,"startDateStruct":404,"completionDateStruct":406,"leadSponsor":408,"locationsCount":40},"100563079","phase-2-glycemic-regulation-as-endometriosis-adjunct-treatment-100563079","NCT06611501","Glycemic Regulation as Endometriosis Adjunct Treatment","GREAT","Inclusion Criteria:\n\n* Female with surgically confirmed endometriosis, determined at laparoscopy\n* Current use for at least 2 months duration of a consistent hormonal therapy for endometriosis (either combination hormonal contraceptives or progestin-only therapy)\n* Current pelvic pain (score ≥ 3 on Visual Analog Scale) that has been present for at least 2 months prior to enrollment\n* Age 15 years to 35 years and premenopausal\n* Willingness to comply with visit schedule and protocol\n\nExclusion Criteria:\n\n* Pre-menarche or post-menopause\n* Diagnosis of Type 1 or Type 2 Diabetes Mellitus\n* Severe renal dysfunction (creatinine \\>1.4 mg\u002FdL or eGFR below 45 mL\u002Fminute\u002F1.73 m2\n* History of lactic acidosis or diabetic ketoacidosis\n* ALT or AST \\> 2.5 times the upper limit of normal\n* Significant mental or chronic systemic illness that might confound pain assessment or the inability to complete the study\n* Current\u002Fplanning pregnancy or breastfeeding\n* Inability to read English","15 Years","35 Years",{"count":389,"type":22},14,[391],"PHASE2","The goal of this pilot trial is to learn if a novel non-hormonal treatment, metformin hydrochloride, works to treat pelvic pain in young women with endometriosis. The main questions it aims to answer are:\n\n* Is metformin superior to placebo in alleviating pain symptoms in young women with endometriosis?\n* Does metformin alter systemic inflammatory markers over 6 months in young women with endometriosis?\n\nResearchers will compare metformin to a placebo (a look-alike substance that contains no drug) to see if metformin works to treat pelvic pain.\n\nParticipants will:\n\n* Take drug metformin or a placebo every day for 6 months\n* Visit the clinic three times: once at baseline (pre-treatment), once at 3 months, and once at 6 months\n* Keep a daily symptom diary to track pain, bleeding, and usage of any pain medications",[26,27],[395,396,397,398,399,27,400,401],"Pelvic pain","Pain","Metformin","Chronic pain","Physiological Effects of Drugs","Female Urogenital Diseases","Genital Diseases, Female",{"date":403,"type":32},"2026-02-20",{"date":405,"type":32},"2025-05-22",{"date":407,"type":22},"2027-01",{"name":409,"class":39},"Boston Children's Hospital",{"id":411,"slug":412,"hasResults":12,"nctId":413,"briefTitle":414,"officialTitle":414,"acronym":4,"eligibilityCriteria":415,"healthyVolunteers":12,"sex":17,"minAge":49,"maxAge":416,"enrollmentInfo":417,"targetDuration":4,"studyType":52,"phases":419,"briefSummary":421,"conditions":422,"keywords":423,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":426,"lastUpdatePostDateStruct":427,"startDateStruct":428,"completionDateStruct":430,"leadSponsor":432,"locationsCount":40},"100600691","phase-3-estradiol-mediated-inflammation-and-central-sensitization-in-the-pathophysiology-of-endometriosis-associated-pelvic-pain-100600691","NCT07100782","Estradiol-mediated Inflammation and Central Sensitization in the Pathophysiology of Endometriosis-associated Pelvic Pain","Inclusion Criteria:\n\n* Premenopausal woman between age 18 and 49 years (inclusive) at the time of consent. Menopause is defined as amenorrhea \\>1 year unrelated to hormonal suppression.\n* History of endometriosis diagnosed by surgery (visual or biopsy confirmed), ultrasound, or MRI within 10 years of study entry\n* History of self-reported moderate to severe pelvic pain for ≥ 6 months' duration at time of screening visit.\n* Willingness to participate in a relugolix CT drug intervention trial\n* Has not used an injectable hormone therapy in the past 6 months (e.g. DepoProvera®, DepoLupron®).\n* Willingness to 30-60 day washout interval of oral, vaginal, transdermal, intrauterine hormonal therapies prior to study initiation if applicable\n* Willingness to use 2 forms of non-hormonal contraception during the entire duration of the study period or has had a history of a bilateral tubal occlusion procedure at least 3 months prior to screening (tubal ligation or hysteroscopic occlusion method)\n* Willing to undergo quantitative sensory testing (QST), fMRI and other study procedures\n* Ability to read and speak English to allow for written informed consent, phenotyping, and patient-reported outcomes measures\n* Meet criteria to participate in QST and fMRI. These include:\n* Normal visual acuity or correctable (with corrective lenses- glasses or contacts) to at least 20\u002F40 for reading instructions in the MRI and visual sensitivity testing\n* No contraindications to MRI (e.g., metal implants, claustrophobia)\n* Willingness to refrain from pain medications such as NSAIDs, acetaminophen, and opioids for 12 hours prior to neuroimaging and QST\n* Willingness to refrain from alcohol and nicotine on day of QST and neuroimaging (alcohol and nicotine consumption is allowed after testing is completed)\n* Willingness to refrain from physical activity or exercise that would cause muscle and\u002For joint soreness for 48 hours prior to testing (routine exercise or activity that does not lead to soreness is acceptable)\n* Able to lie still on their back for 1 hour during MRI\n* Weigh 300 pounds or less.\n\nAdditional inclusion criteria to proceed with Study Visit 2 and clinical trial:\n\n* \\>60% complete entries in daily electronic diary (end-of-day pain, bleeding, fatigue scores)\n* Minimum of two menstrual flows separated by a minimum of 21 days (d1 bleed to next d1 bleed) during the washout\u002Fscreening period\n* Moderate-severe non-menstrual pain and dysmenorrhea confirmed with daily electronic diary in the washout\u002Fscreening period.\n\nExclusion Criteria:\n\n* Contraindication to the use of relugolix CT (high risk of arterial or venous thrombotic, or thromboembolic disorder, known osteoporosis, current or history of breast cancer or other hormone sensitive malignancy, known hepatic impairment or disease, undiagnosed abnormal uterine bleeding, known hypersensitivity to components of relugolix CT).\n* Concurrent participation in other therapeutic trials\n* Pregnant, lactating, less than 6 months postpartum, or planning a pregnancy within next 12 months\n* Planning pelvic or abdominal surgery during study period\n* Prior major surgery in the past 4 months that involves incisions on the abdomen, chest, head, other than a skin biopsy (hysteroscopy, endometrial biopsy is ok to include).\n* Planning to initiate a new adjunctive pain treatment during study treatment (e.g. cognitive behavioral therapy, physical therapy, acupuncture). Participants may be enrolled if these treatments are completed prior to trial or using stable therapies.\n* History of hysterectomy and\u002For bilateral oophorectomy\n* Clinically significant gynecologic condition such as significant endometrial pathology (e.g. endometrial hyperplasia), persistent ovarian cyst larger than 5 cm, largest uterine dimension \\>15 centimeters and not planning an additional intervention or treatment for endometriosis, or another uterine or ovarian condition during the study period. Patients may be enrolled in this study if they were previously successfully treated for these conditions. Patients must have undergone pelvic ultrasound or MRI in the past 6 months, and provide results (or release of records to obtain results)\n* History or current evidence of psychosis, current suicide risk or attempt within 2 years of study (note: participants with mood disorders such as depression or anxiety will not be excluded)\n* Chronic opioid, alcohol, and\u002For illicit drug use\n* History of substance abuse within past one year\n* Unable or unwilling to discontinue opioids analgesics within 48 hours of the dense phenotyping study visits\n* Medical conditions that may significantly interfere with relugolix CT efficacy, ability to fully comply or would make it unsafe for participants to take part in the study, including but not limited to: morbid obesity with Body Mass Index \\> 45, uncontrolled autoimmune\u002Finflammatory diseases, significant cardiopulmonary disease (e.g., angina, congestive heart failure, uncontrolled hypertension, severe cardiac valvular disease, Chronic Obstructive Pulmonary Disease (COPD), chronic asthma), renal or liver disease (e.g. cirrhosis, hepatitis), uncontrolled endocrine or allergic disorders (e.g., hypothyroidism, diabetes, allergic rhinitis), neurologic conditions (e.g., multiple sclerosis, prior stroke, neurological tumor), severe physical impairment (e.g., blindness, deafness, paraplegia); and active malignancy (any malignancy except for localized dermatologic cancer).\n* Any impairment, activity or situation that in the judgment of the Study Coordinator or Principal Investigator would prevent safe or satisfactory completion of the study protocol.\n* Individuals receiving or applying for compensation or disability and other aspects associated with potential secondary gain per self-report;\n* Additional exclusion that prevent participation in QST and fMRI:\n\n  1. Severe claustrophobia precluding MRI and evoked pain testing during scanning;\n  2. Diagnosed peripheral neuropathy\n  3. Diagnosed epilepsy\n  4. Diagnosed or self-reported visual-evoked migraines can participate in study, but will not participate in the visual testing procedures.\n  5. Weigh \\>300 pounds","49 Years",{"count":418,"type":22},130,[420],"PHASE3","The purpose of this study is to better understand how hormone suppression with Relugolix Combination-Therapy (CT) affects pelvic pain, inflammation, and pain sensitivity in women with moderate-to-severe endometriosis associated pelvic pain.",[27,26],[424,425],"Relugolix Combination Therapy","Endo-EPIC (Alternative study acronym\u002Ftitle)","2026-02-13",{"date":239,"type":32},{"date":429,"type":32},"2025-12-08",{"date":431,"type":22},"2028-09",{"name":433,"class":39},"University of Michigan",{"id":435,"slug":436,"hasResults":12,"nctId":437,"briefTitle":438,"officialTitle":439,"acronym":4,"eligibilityCriteria":440,"healthyVolunteers":12,"sex":17,"minAge":49,"maxAge":79,"enrollmentInfo":441,"targetDuration":4,"studyType":52,"phases":443,"briefSummary":444,"conditions":445,"keywords":450,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":456,"lastUpdatePostDateStruct":457,"startDateStruct":459,"completionDateStruct":461,"leadSponsor":463,"locationsCount":40},"100619994","effects-of-pemm-in-chronic-low-back-pain-women-with-urinary-incontinence-100619994","NCT07351851","Effects of PEMM in Chronic Low Back Pain Women With Urinary Incontinence","Effects of PEMM in Chronic Low Back Pain Women With Urinary Incontinence A Randomised Controlled Trial","Inclusion Criteria:\n\n* Age group of 18 - 65 years\n* Has child\u002Fchildren \\\u003C5 parity\n* CLBP patients with UI referred for physiotherapy for CLBP\n* Patient with low back pain for more than 3 months\n* NRS more than 5\u002F10\n* Patient with complain of urinary incontinence since past 3 months or more\n\nExclusion Criteria:\n\n* Chronic Low Back Pain with red flags\n* Not able to read and write in English \u002FArabic\n* Pregnant ladies and post partum 1 year\n* UTI, Pelvic floor Surgery\n* Any systemic condition of renal and cardiac\n* Patient with active carcinoma or any inflammatory disease",{"count":442,"type":22},200,[54],"Urinary incontinence (UI), Chronic low back pain (CLBP) in women are prevalent and often coexist. Multiple conditions when coexist, it leads to reduced Quality of life in turn causing physical and mental impairment. Musculoskeletal structures and fascial restrictions is one of the attribute to the coexistence of urinary incontinence and chronic back pain in women. External myofascial mobilization (EMM) with core exercises have been proven beneficial for conditions in males that is caused by musculoskeletal and fascial structures. However there are limited research which proves the effect of EMM in conditions involving musculoskeletal and fascial structures . Therefore, the aim of the study is to find the effect of MFTs in reducing the disability in women with CLBP and UI PRIMARY OBJECTIVE To evaluate the effectiveness of PEMM treatment in reducing disability, pain and improving mental health in women with CLBP and UI Study design : Simple randomization Sampling method: Simple Random sampling Random numbers will be generated in Excel, then random numbers will be presented in a concealed envelope for the participants to choose Sample Size : 130 (Experimental 65, Control 65) Sample size was determined using expected effect size i.e., mean change in the primary outcome variable disability index reported in the recent research study . With effect size (change in the disability index score) 3.5 and standard deviation of the change in the outcome 6.45, statistical power 80% and level of significance 5%, the required sample size would be n=55 participants in each group. However, to accounts for multiple secondary outcome measures, possible dropouts and non-response it would be good to increase an additional 20% in calculated sample size i.e., a total of 130 participants (65 participants in each group) will be included in this study.\n\nThe following sample size equation was used to determine adequate sample size:n = \\[2 (Z?\u002F2 + Z?)2 \\* ?2\\] \u002F (m1-m2)2 Where Z? and Z? are the values standard normal variate e.g., at 5% level of significance Z?\u002F2 = 1.96, and with 80% power the value of Z?= 0.84; ? is the polled Standard deviation and m1 and m2 are the mean outcome values s in group 1 and group 2 respectively.\n\nBlinding:\n\nSingle blinding: patient will be blinded to the group allocation. The assessor is blinded to the treatment\n\nMaterial and tools :\n\nTheragun - Theragun Elite, 20 V, Myofascial tools - foam roll, foam ball, Questionnaires - SF 3642,43,44, Oswestry Low back pain questionnaire (ODI)45 and The International Consultation on Incontinence Questionnaire Urinary Incontinence Short Form (ICIQ-UI-SF)46 PROCEDURE In the course of the study the total number of patients referred to physiotherapy department with LBP will be interviewed to identify patients with or without UI having LBP. The data obtained from this will be recoded as prevalence in results. The documents of the patients having LBP with UI will be reviewed to check who fulfills the inclusion criteria. All who meets the inclusion criteria will be approached face to face with the aim of the study. Informed consent form will be given to patients who are volunteering to participate in the study. The data of the participants who do not wish to participate in the study will also be recorded.\n\nThe participants who have consented to participate in the study will be then assessed. Since the participants has UI she will be directed to a Urologist for an assessment. After urologist assessment, patients will be randomly allocated to experimental and control groups. Random allocation will be administered by the random numbers generated and will be presented in a concealed envelope for the participants to choose. 1st week, the demographic data and Outcome measure of pain, SF36, ODI, ICIQ-UI-SF will be recorded (1st time) on the day of assessment. The outcome measures will be printed on paper and will be given to the patients to fill up with a pen, all questionnaires are self reported outcome measures. Treatment will commence a week after, where experimental group will undergo PEMM therapy with strengthening for 6 weeks duration and the control group will have conventional symptomatic pain treatment with strengthening (2nd to 7th week). Treatment will be given for 6 weeks (1 sessions in a week). The treatment day may vary any day between 4th and 7th day post one session. After 6 sessions of treatment, patient will be advised HEP (Home exercise program) to continue at home. Reassessment will be done on the 8th week where the outcome measures of pain, SF36, ODI, ICIQ-UI-SF will be recorded. Participants will be educated and advised regarding HEP. Exercises will be taught to the patient by explanation, demonstration, teach-back method, and printed sheet of exercise. Compliance to HEP will be recorded before final Outcome measure",[446,447,448,449,26],"Chronic Low-back Pain (cLBP)","Urinary Incontinence (UI)","Pelvic External Myofascial Mobilisation","Myofascial Techniques",[451,452,453,454,455],"chronic low back pain","urinary incontinence","myofascial mobilisation","PEMM","female pelvic pain","2026-01-11",{"date":458,"type":32},"2026-01-20",{"date":460,"type":32},"2025-09-29",{"date":462,"type":22},"2027-12",{"name":464,"class":113},"Hamad Medical Corporation",{"id":466,"slug":467,"hasResults":12,"nctId":468,"briefTitle":469,"officialTitle":470,"acronym":471,"eligibilityCriteria":472,"healthyVolunteers":12,"sex":17,"minAge":49,"maxAge":473,"enrollmentInfo":474,"targetDuration":4,"studyType":52,"phases":475,"briefSummary":476,"conditions":477,"keywords":478,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":483,"lastUpdatePostDateStruct":484,"startDateStruct":486,"completionDateStruct":488,"leadSponsor":490,"locationsCount":40},"100558351","interdisciplinary-group-care-for-the-treatment-of-endometriosis-associated-pain-100558351","NCT06549985","Interdisciplinary Group Care for the Treatment of Endometriosis-associated Pain","Interdisciplinary Group Care for the Treatment of Endometriosis-associated Pain: the Peer Empowered Endometriosis Pain Support (PEEPS) Pilot Randomized Controlled Trial","PEEPS RCT","Inclusion Criteria:\n\n* Age 18-48 years\n* Operative confirmation of endometriosis\n* Chronic pelvic pain (pain perceived to originate from the pelvis, not exclusively during menses, lasting ≥6 months)\n* No plan to have surgery before or during the PEEPS cohort\n* Able to attend at least six of the eight 2-hour weekly sessions on the Washington University campus\n* Comfort reading and speaking English as groups and materials are in English\n\nExclusion Criteria:\n\n* Currently pregnant\n* Severe physical impairment (limiting yoga participation)\n* History of hip or spine surgery given increased risk of harm and need for extensive activity modification\n* Current or history of psychiatric disorder with psychosis in order to minimize risk of adverse mental health effects to participants\n* Opioid use ≥ 5 days in the past 3 months, other than for the 6-week post-operative period\n* History of surgical removal of bilateral ovaries","48 Years",{"count":225,"type":22},[54],"The goal of this clinical trial is to determine if Peer Empowered Endometriosis Pain Support (PEEPS), an 8-week interdisciplinary, integrative group care program, decreases pain interference in participants with endometriosis-associated chronic pelvic pain between the ages 18 and 48. The main question we aim to answer is:\n\nIs PEEPS more effective than Education in decreasing pain interference?\n\nResearchers will compare people receiving PEEPS plus usual care to those receiving Education plus usual care to see if people participating in PEEPS demonstrate improvements in pain, physical function, and quality of life.\n\nParticipants will:\n\n* Complete baseline quality of life surveys\n* Participate in an 8-session group care program\n* Provide feedback on each session and the program globally\n* Complete follow up quality of life surveys at PEEPS completion, 6- and 12-months post-completion.\n* A sub-set will complete semi-structured interviews or focus groups about the experience of participating in PEEPS",[27,26],[479,480,139,481,482],"Group care","Integrative care","Mindfulness","Patient-centered outcomes","2025-12-18",{"date":485,"type":32},"2025-12-26",{"date":487,"type":32},"2025-03-17",{"date":489,"type":22},"2028-09-30",{"name":38,"class":39},{"id":492,"slug":493,"hasResults":12,"nctId":494,"briefTitle":495,"officialTitle":496,"acronym":497,"eligibilityCriteria":498,"healthyVolunteers":12,"sex":17,"minAge":49,"maxAge":19,"enrollmentInfo":499,"targetDuration":4,"studyType":52,"phases":501,"briefSummary":502,"conditions":503,"keywords":504,"overallStatus":148,"whyStopped":4,"lastUpdateSubmitDate":510,"lastUpdatePostDateStruct":511,"startDateStruct":512,"completionDateStruct":514,"leadSponsor":516,"locationsCount":4},"100616393","pelvic-pain-electro-acupuncture-100616393","NCT07305025","Pelvic Pain Electro-Acupuncture","Pelvic Pain Electro-Acupuncture: Randomized Study for Symptom Liberation","PEARL","Inclusion Criteria:\n\n* Women aged 18-45 years referred for diagnostic laparoscopy with suspicion of endometriosis\n* Experiencing moderate to severe pelvic pain\n* Willing to commit to the treatment schedule and follow-up\n* Understanding Norwegian or English to be able to communicate and fill out questionnaires\n\nExclusion Criteria:\n\n* Pregnancy\n* Use of opioid pain relief\n* Concurrent participation in other pain management trials",{"count":500,"type":22},38,[54],"The aim of the study is to investigate if a series of up to 9 treatment sessions of electroacupuncture can be used to alleviate pain in women with suspected endometriosis, scheduled for diagnostic laparoscopy",[26,27],[505,506,260,507,508,509],"pelvic pain","endometriosis","sexual function","quality of life","pelvic floor muscle function","2025-12-11",{"date":485,"type":32},{"date":513,"type":22},"2025-12-15",{"date":515,"type":22},"2027-04-30",{"name":517,"class":39},"St. Olavs Hospital",{"id":519,"slug":520,"hasResults":12,"nctId":521,"briefTitle":522,"officialTitle":523,"acronym":4,"eligibilityCriteria":524,"healthyVolunteers":78,"sex":17,"minAge":49,"maxAge":79,"enrollmentInfo":525,"targetDuration":4,"studyType":52,"phases":527,"briefSummary":528,"conditions":529,"keywords":530,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":533,"lastUpdatePostDateStruct":534,"startDateStruct":536,"completionDateStruct":538,"leadSponsor":540,"locationsCount":40},"100611519","effect-of-tele-yoga-on-pain-fatigue-and-quality-of-life-in-endometriosis-100611519","NCT07241637","Effect of Tele-Yoga on Pain, Fatigue, and Quality of Life in Endometriosis","The Effect of Tele-Yoga Application on Chronic Pelvic Pain, Fatigue and Quality Of Life In Women With Endometriosis Diagnosis","Inclusion Criteria:\n\n* Voluntarily agree to participate in the research\n* Able to communicate effectively and have no language barriers\n* Have at least a primary school education\n* Are 18 years of age or older and premenopausal\n* Are not pregnant\n* Have no health problems that would prevent them from practicing yoga\n* Do not exercise regularly \u002F do not exercise more than three times per week\n* Have not received physical therapy within the past three months\n* Have not undergone any pelvic surgery within the past year\n* Do not have surgical treatment planned for endometriosis\n* Do not have any other injury or disease causing pelvic pain\n* Have mild (1-3) or moderate (4-6) chronic pelvic pain\n* Have access to a computer, phone, or tablet with a camera and an available internet connection to participate in online sessions\n\nExclusion Criteria:\n\n* Those who wish to withdraw at any stage of the research\n* Those who do not attend all Tele-yoga sessions\n* Those who begin regular exercise or physical therapy during the study period\n* Those who become pregnant during the study\n* Those who use any Complementary or Alternative Medicine (CAM) method during the intervention\n* Those who undergo surgical treatment during the course of the study",{"count":526,"type":22},66,[54],"This study aims to examine the effects of Tele-yoga on chronic pelvic pain, fatigue, and quality of life in patients diagnosed with endometriosis. It will be conducted as a single-center, randomized controlled experimental study design.",[26,27],[26,531,532,59,27],"Yoga","Fatigue","2025-11-20",{"date":535,"type":32},"2025-11-25",{"date":537,"type":32},"2025-09-01",{"date":539,"type":22},"2026-06-30",{"name":541,"class":39},"Ankara University",{"id":543,"slug":544,"hasResults":12,"nctId":545,"briefTitle":546,"officialTitle":546,"acronym":547,"eligibilityCriteria":548,"healthyVolunteers":12,"sex":17,"minAge":49,"maxAge":4,"enrollmentInfo":549,"targetDuration":551,"studyType":23,"phases":4,"briefSummary":552,"conditions":553,"keywords":555,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":558,"lastUpdatePostDateStruct":559,"startDateStruct":561,"completionDateStruct":563,"leadSponsor":565,"locationsCount":40},"100611669","cohort-of-the-franco-european-multidisciplinary-institute-of-endometriosis-100611669","NCT07243587","Cohort of the Franco-European Multidisciplinary Institute of Endometriosis","IFEMEndo","Inclusion Criteria:\n\n* Women aged \\>18 years\n* Women with histologically or radiologically confirmed deep endometriosis (and\u002For) infiltrating the colon and\u002For rectum\n* Women affiliated with the social security system\n\nExclusion Criteria:\n\n* Refusal to participate\n* Patients under guardianship or curatorship, or deprived of liberty",{"count":550,"type":22},15000,"10 Years","Endometriosis is a chronic benign gynecological condition affecting 5 to 10% of women of reproductive age, often responsible for pelvic pain, digestive symptoms, and infertility, leading to a significant reduction in quality of life. Despite its high prevalence, the long-term outcomes of different medical and surgical treatments remain poorly documented.\n\nThe IFEMENDO study is a prospective, observational, single-center, non-interventional cohort conducted at the Endometriosis Center of Clinique Tivoli-Ducos in Bordeaux, France. The objective is to evaluate the long-term efficacy of various therapeutic strategies-both medical and surgical-in terms of symptom improvement, quality of life, recurrence, and fertility outcomes.\n\nWomen with histologically or radiologically confirmed pelvic endometriosis are invited to participate. Data are collected through standardized questionnaires at baseline and at 1, 3, 5, 7, and 10 years after inclusion, either via the secure NO ENDO online platform or in paper form. The study will contribute to a better understanding of the natural history of endometriosis and the long-term effectiveness of different treatment approaches, ultimately supporting improvements in clinical management and patient care.",[27,554,26],"Deep Endometriosis",[556,557],"cohort","prospective","2025-11-17",{"date":560,"type":32},"2025-11-24",{"date":562,"type":32},"2021-02-01",{"date":564,"type":22},"2036-02",{"name":566,"class":39},"Clinique Tivoli Ducos",{"id":568,"slug":569,"hasResults":12,"nctId":570,"briefTitle":571,"officialTitle":572,"acronym":4,"eligibilityCriteria":573,"healthyVolunteers":12,"sex":17,"minAge":49,"maxAge":4,"enrollmentInfo":574,"targetDuration":4,"studyType":52,"phases":575,"briefSummary":576,"conditions":577,"keywords":578,"overallStatus":148,"whyStopped":4,"lastUpdateSubmitDate":580,"lastUpdatePostDateStruct":581,"startDateStruct":583,"completionDateStruct":585,"leadSponsor":587,"locationsCount":40},"100488670","hyivy-device-as-non-hormonal-therapy-in-endometriosis-100488670","NCT05643131","Hyivy Device as Non-hormonal Therapy in Endometriosis","Evaluation of the Hyivy Device as a Non-hormonal Therapy in People With Endometriosis","Inclusion Criteria:\n\n* 1.Age ≥ 18 at the time of enrollment\n* 2.Generally in good health (other than due to endometriosis), at physician's discretion\n* 3.Diagnosed with endometriosis (clinical, radiologic, or surgical)\n* 4.Diagnosed with chronic pelvic pain (self-reported pain in pelvic area lasting \\>3 months)\n* 5.VAS for overall pelvic pain ≥ 4 at screening and baseline\n* 6.Medically managing endometriosis using continuous hormonal medications (i.e., oral contraceptive pills, progesterone only pills, Mirena, GnRH agonists\u002Fantagonists) for at least 3 months prior to enrollment\n* 7.Agrees not to commence any new treatments (medical or physical therapies) for the 12-week intervention period, including hormonal therapies for any medical condition, and complimentary and\u002For alternative management of surgery for endometriosis and associated chronic pain\n* 8.Agrees not to undergo pelvic physiotherapy with a trained professional during the study\n* 9.Agrees to avoid taking non-steroidal anti-inflammatory drugs (e.g., ibuprofen) for 72 hours before Visits 1, 2, and 3\n* 10.Must have the ability to charge the investigational device\n* 11.Must be willing and able to insert intravaginal device\n* 12.Able to understand, comply and consent to protocol requirements and instructions\n* 13.Able to attend scheduled study visits and complete required investigations\n\nExclusion Criteria:\n\n* 1.Chronic pelvic pain thought to be due to a condition other than endometriosis\n* 2.Diagnosis of premature ovarian insufficiency\n* 3.Any other medical condition or clinical finding giving reasonable suspicion of a disease or condition that contraindicates the use of the investigational product or that may affect the interpretation of the results or leave the patient at high risk from treatment complications, at the discretion of the investigator(s)\n* 4.Any surgery in the past 3 months or anticipates having surgery during the study\n* 5.Allergy to Hyivy device's materials\n* 6.Active vaginal infection (e.g. vulvovaginal candidiasis, trichomonas vaginitis, bacterial vaginosis, STIs) or infection in the pelvic area\n* 7.Current use of antibiotics and a history of vulvovaginal candidiasis\n* 8.Pregnant or lactating\n* 9.Currently under the care of a pelvic floor physiotherapist\n* 10.Have open wounds, cuts, or open sores present in vaginal or pelvic area\n* 11.Severe atrophic vaginitis or very dry, itchy, or sore vagina\u002Fvaginal area, at the discretion of the primary investigator(s)\n* 12.Hypoesthesia or loss in sensation of the pelvic floor\n* 13.Total and\u002For partial prolapse of the uterus and\u002For vagina\n* 14.Symptoms of severe urinary retention, severe extra-urethral incontinence or overflow incontinence\n* 15.Unable to position the device according to directions for use\n* 16.Use of any medical devices that may interfere with the investigational device's function, such as pacemakers, ventilators, and ear implants",{"count":361,"type":22},[54],"This study seeks to address accessible management of endometriosis-associated chronic pelvic pain by evaluating a novel device used in the home. The study is designed as a proof-of-concept single-arm pilot study, and the primary objective is to assess change in overall self-reported pelvic pain in people with endometriosis-associated chronic pelvic pain following the use of the Hyivy intravaginal device.",[27,26],[27,26,579],"Dilator","2025-09-11",{"date":582,"type":32},"2025-09-17",{"date":584,"type":22},"2025-10",{"date":586,"type":22},"2026-12",{"name":588,"class":113},"Hyivy Health Inc",{"id":590,"slug":591,"hasResults":12,"nctId":592,"briefTitle":593,"officialTitle":594,"acronym":595,"eligibilityCriteria":596,"healthyVolunteers":78,"sex":17,"minAge":49,"maxAge":279,"enrollmentInfo":597,"targetDuration":4,"studyType":52,"phases":598,"briefSummary":599,"conditions":600,"keywords":604,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":612,"lastUpdatePostDateStruct":613,"startDateStruct":615,"completionDateStruct":617,"leadSponsor":619,"locationsCount":40},"100456525","platelet-rich-plasma-for-uterine-scar-100456525","NCT05224726","Platelet Rich Plasma for Uterine Scar","Platelet Rich Plasma for the Treatment of Uterine Scar","AA-PRP","Inclusion criteria:\n\n* Women undergoing elective cesarean delivery\n* Term pregnancy (≥37 weeks of gestation)\n\nExclusion criteria:\n\n* Thrombocytopenia (CBC Platelet count \\\u003C70,000)\n* Connective tissue disease\n* Uterine scars other than cesarean (s\u002Fp myomectomy, s\u002Fp cornual resection)\n* Malformed uterus (unicornuate, bicornuate, didelphic)",{"count":338,"type":22},[54],"When vessel wall injury occurs, platelets become activated, releasing more than 30 bioactive proteins, many of which have a fundamental role in hemostasis, inflammation and ultimate wound healing. Platelet-rich plasma (PRP), a modification of fibrin glue made from autologous blood, is being used to deliver growth factors in high concentration to sites requiring wound healing. PRP is obtained from a sample of patients' blood drawn at the time of treatment. As the rate of cesarean deliveries has been rising, long-term adverse sequelae due to uterine scar defects have been increasing. PRP might be a simple preventive treatment that potentially can reduce morbidity following cesarean deliveries.",[601,602,26,603],"Cesarean Section Complications","Uterine Bleeding","Menstrual Irregularity",[605,606,505,607,608,609,610,611],"uterine scar defect","cesarean delivery","spotting","niche","cesarean section complication","uterine scar","Platelet Rich Plasma (PRP)","2025-08-24",{"date":614,"type":32},"2025-08-26",{"date":616,"type":32},"2025-07-19",{"date":618,"type":22},"2028-07-01",{"name":620,"class":39},"The University of Texas Health Science Center, Houston",{"id":622,"slug":4,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":623,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":624,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":625,"lastUpdatePostDateStruct":626,"startDateStruct":628,"completionDateStruct":629,"leadSponsor":630,"locationsCount":40},"100523868",{"count":21,"type":22},[26,27],"2025-08-11",{"date":627,"type":32},"2025-08-13",{"date":34,"type":32},{"date":36,"type":22},{"name":38,"class":39},{"id":632,"slug":633,"hasResults":12,"nctId":634,"briefTitle":635,"officialTitle":636,"acronym":637,"eligibilityCriteria":638,"healthyVolunteers":12,"sex":17,"minAge":49,"maxAge":387,"enrollmentInfo":639,"targetDuration":4,"studyType":52,"phases":641,"briefSummary":642,"conditions":643,"keywords":644,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":648,"lastUpdatePostDateStruct":649,"startDateStruct":650,"completionDateStruct":652,"leadSponsor":654,"locationsCount":40},"100582331","phase-4-nsaid-use-for-treating-dysmenorrhea-and-preventing-chronic-pelvic-pain-nsaid-heal-100582331","NCT06861920","NSAID Use for Treating Dysmenorrhea and Preventing Chronic Pelvic Pain (NSAID HEAL)","Targeting Interindividual Variability in NSAID Responses to Mitigate Chronic Pelvic Pain Risk in Dysmenorrhea (NSAID HEAL)","NSAIDHEAL","Inclusion Criteria:\n\n* aged 18-35\n* individuals who menstruate, with painful periods\n* regular menstrual cycles (every 22-35 days)\n\nExclusion Criteria:\n\n* presence of active pelvic or abdominal malignancies (primary or metastatic)\n* conditions associated with the absence of regular menses such as polycystic ovarian syndrome, pregnancy, or any current use of continuous hormonal medication or contraceptive\n* unable to read or comprehend the informed consent in English\n* presence of other diagnosed chronic back or pelvic pain conditions (including chronic back pain, fibromyalgia, bladder pain syndrome, irritable bowel syndrome, vulvar pain syndrome, and endometriosis-associated pelvic pain)\n* having another diagnosed\u002Fsymptomatic chronic pain condition besides migraines with an average pain score \\>3\u002F10 in the last month when not consuming pain relievers, or that requires daily treatment with opioids (ex. hydrocodone, oxycodone, codeine, morphine, hydromorphone, tapentadol, tramadol) or neuromodulators (also known sometimes as antidepressants \\[ex. amitriptyline, nortriptyline, imipramine, duloxetine, milnacipran, venlafaxine\\] or antiseizure medications \\[ex. topiramate, gabapentin, pregabalin, carbamazepine, lamotrigine\\])\n* current or past history of stomach ulcers\n* current or past history of gastrointestinal (GI) bleeding\n* diagnosis of peptic ulcer disease\n* current or past history of renal disorders\n* current or past history of adrenal dysfunction\n* diagnosis of liver disorders\n* diagnosis of chronic acid reflex (i.e. GERD)\n* Diagnosis of Crohn's disease or ulcerative colitis\n* Coagulopathy\n* Prolactinoma\n* Von Willebrand disease\n* Platelet disorders\n* High blood pressure that is difficult to manage\n* gastrointestinal conditions or surgeries that affect naproxen absorption\n* bleeding disorders\n* heart failure\n* a history of stroke\n* a history of heart attack\n* active genitourinary or sexually transmitted infection\n* allergy to non-steroidal anti-inflammatory drugs (NSAIDs) or their ingredients\n* individuals who take the following medications: anticoagulants (i.e. warfarin), lithium, diuretics, antacids, angiotensin-converting enzyme (ACE) inhibitors, methotrexate, cholestyramine, or probenecids.\n* Unmanaged diabetes (i.e. Fasting Blood Glucose: ≥ 126 mg\u002FdL (≥ 7.0 mmol\u002FL), Non-Fasting\u002FRandom Blood Glucose: ≥ 200 mg\u002FdL (≥ 11.1 mmol\u002FL), Hemoglobin A1c (HbA1c): ≥ 6.5%)\n* Uncontrolled thyroid function (i.e. Hypothyroidism (Underactive Thyroid): Thyroid-Stimulating Hormone (TSH): \\> 4.5 mIU\u002FL (mild) or \\> 10 mIU\u002FL (severe) Free T4: Below the lower end of the reference range (usually \\\u003C 0.9 ng\u002FdL)\n* Hyperthyroidism (overactive thyroid) (i.e. TSH: \\\u003C 0.4 mIU\u002FL (Suppressed or undetectable), Free T4: Above the upper end of the reference range (usually \\> 2.0 ng\u002FdL)\n* Liver dysfunction (i.e. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) or bilirubin (unless known diagnosis of Gilbert's syndrome) ≥ 1.5 times the upper limit of the reference range)\n* Kidney dysfunction (i.e. Serum creatinine \\> 1.1 mg\u002FdL.)",{"count":640,"type":22},600,[171],"The goal of this clinical trial is to learn if NSAIDs (i.e. naproxen sodium) can treat menstrual pain and prevent the development of chronic pelvic pain in menstruating adults with painful periods. The main questions it aims to answer are:\n\n* Can non-menstrual pelvic pain reduction be predicted by menstrual pain response to NSAIDs?\n* Will participants with the largest reductions in multi-site sensitivity following NSAID therapy have the largest reductions in non-menstrual pelvic pain?\n\nResearchers will compare naproxen sodium to a placebo (a look-alike substance that contains no drug) to see if naproxen sodium works to treat painful periods.\n\nParticipants will:\n\n* Take naproxen sodium or placebo during several days of their menstrual period every month for 1 year.\n* Complete computer questionnaires and tests from home every 3 months.\n* Complete at-home urine tests to measure hormones every few days for 1-year.\n* Use a pin-prick to collect a small spot of blood, and use a pad or tampon to collect a sample of menstrual blood, and bring it to the research site twice over a 1-year period.\n* Come to the research site twice over a 1-year period to complete sensory assessments and undergo a blood draw.\n\nThe major goal of the study is to develop a multivariable statistical model (see https:\u002F\u002Fgrants.nih.gov\u002Fgrants\u002Fguide\u002Frfa-files\u002FRFA-NS-24-021.html ) describing the factors that effectiveness of pain medication and risk for chronic pain",[86,127,26],[645,646,127,26,647],"Painful Periods","NSAIDs","Periods","2025-08-04",{"date":349,"type":32},{"date":651,"type":32},"2025-04-07",{"date":653,"type":22},"2030-07",{"name":655,"class":39},"Endeavor Health",{"id":657,"slug":658,"hasResults":12,"nctId":659,"briefTitle":660,"officialTitle":660,"acronym":661,"eligibilityCriteria":662,"healthyVolunteers":78,"sex":17,"minAge":49,"maxAge":19,"enrollmentInfo":663,"targetDuration":4,"studyType":52,"phases":665,"briefSummary":666,"conditions":667,"keywords":4,"overallStatus":148,"whyStopped":4,"lastUpdateSubmitDate":670,"lastUpdatePostDateStruct":671,"startDateStruct":673,"completionDateStruct":675,"leadSponsor":677,"locationsCount":4},"100599244","effect-of-the-bioheat-patch-on-pain-following-the-hyfosy-procedure-100599244","NCT07081971","Effect of the Bioheat Patch on Pain Following the HyFoSy Procedure","B-HyP","Inclusion Criteria:\n\nWomen aged 18-45 scheduled for HyFoSy\n\nNo dermatologic conditions at the patch site\n\nNo allergies to patch ingredients, or heat\n\nNo active pelvic infections\n\nExclusion Criteria:\n\nActive genital infection\n\nSkin issues in lower abdomen\n\nSensitivity to heat\n\nAny medical condition preventing local heat use",{"count":664,"type":22},80,[54],"This randomized controlled trial (RCT) evaluates the efficacy of Bioheat thermal patches in reducing post-procedural pain following Hysterosalpingo Foam Sonography (HyFoSy).\n\nHyFoSy is a common ultrasound-based diagnostic procedure to assess tubal patency and uterine cavity structure in women undergoing fertility workup. While generally less painful than HSG, many patients still report moderate to severe cramping and discomfort during and after the test.\n\nThermal therapy has demonstrated effectiveness in reducing musculoskeletal and gynecological pain. Bioheat patches, approved by the Israeli Ministry of Health for menstrual pain relief, emit safe, low-grade heat (approximately 37-38°C) and may provide a non-invasive pain management strategy post-HyFoSy.\n\nParticipants (n=80) will be women aged 20-45 undergoing HyFoSy. They will be randomly assigned to either the Bioheat intervention group or a placebo patch group, applied externally to the lower abdomen. The heat-producing patch contains iron and other safe materials that react with oxygen to emit continuous heat without electricity. Infrared radiation from the patch components may also promote local vasodilation and muscle relaxation.\n\nPain assessment will use the validated Visual Analog Scale (VAS), collected post-procedure via follow-up SMS and phone contact. The study aims to quantify reduction in perceived pain, and potentially improve patient satisfaction with HyFoSy. Safety has been pre-established, with no reported adverse skin effects when used as instructed.\n\nStudy duration is six months, following ethics approval at the OB-GYN ultrasound department of Shamir Medical Center.",[26,668,287,669],"Infertility","Gynecologic Procedures","2025-07-28",{"date":672,"type":32},"2025-07-30",{"date":674,"type":22},"2025-08-01",{"date":676,"type":22},"2025-12-30",{"name":678,"class":679},"Assaf-Harofeh Medical Center","OTHER_GOV",{"id":681,"slug":682,"hasResults":12,"nctId":683,"briefTitle":684,"officialTitle":685,"acronym":686,"eligibilityCriteria":687,"healthyVolunteers":12,"sex":17,"minAge":49,"maxAge":4,"enrollmentInfo":688,"targetDuration":4,"studyType":52,"phases":689,"briefSummary":690,"conditions":691,"keywords":696,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":705,"lastUpdatePostDateStruct":706,"startDateStruct":708,"completionDateStruct":710,"leadSponsor":712,"locationsCount":40},"100580670","vibrating-vs-traditional-therapy-for-treatment-of-entry-dyspareunia-100580670","NCT06840314","VIBRating vs Traditional Therapy for Treatment of ENTry Dyspareunia","VIBRENT- VIBRating vs Traditional Therapy for Treatment of ENTry Dyspareunia","VIBRENT","Inclusion Criteria:\n\n* Assigned female at birth\n* Age ≥ 18 years old\n* Genito-pelvic pain\u002Fpenetration disorder (per ICD-10 diagnosis codes: F52.5 Vaginismus not due to a substance or known physiological condition, F52.6 Dyspareunia not due to a substance or known physiological condition, N94.1 Dyspareunia, N94.2 Vaginismus, N94.81 Vulvodynia)\n\nExclusion Criteria:\n\n* Current or prior use of a therapeutic vaginal device used to treat GPPPD\n* Unmanaged genitourinary syndrome of menopause\n* History of pelvic radiation\n* History of genital tract malignancy\n* History of female genital mutilation\n* History of prior surgery for prolapse or incontinence, including vaginal mesh or midurethral sling mesh\n* Silicone allergy",{"count":225,"type":22},[54],"The goal of this randomized controlled trial is to determine whether the use of a novel vibrating pelvic floor therapeutic device (\"Kiwi\") improves sexual function in sexually active women aged 18 and older with genito-pelvic pain and penetration disorder (GPPPD) more effectively than traditional vaginal dilators.\n\nThe main questions it aims to answer are:\n\n1. Does the use of the Kiwi device lead to higher sexual function scores compared to traditional vaginal dilators\n2. Does the Kiwi device improve sexual distress, pain, and overall symptom severity more effectively than traditional vaginal dilators?\n\nResearchers will compare the Kiwi vibrating device to traditional cylindrical vaginal dilators to assess whether the Kiwi device results in greater improvements in sexual function and symptom relief.\n\nParticipants will:\n\n* Be randomly assigned to use either the Kiwi device or traditional vaginal dilators.\n* Use the assigned device three times per week for 15 minutes per session over four weeks.\n* Complete surveys before and after the study, including assessments of sexual function, pain, and overall improvement.",[692,365,693,26,694,695],"Genito-Pelvic Pain\u002FPenetration Disorder","Vaginismus","Vestibulodynia","Vulvodynia (Chronic Vulvar Pain)",[697,698,699,700,505,701,702,703,704],"genito-pelvic pain\u002Fpenetration disorder","dyspareunia","entry dyspareunia","vaginismus","female sexual function","pain with sex","vulvodynia","vestibulodynia","2025-05-16",{"date":707,"type":32},"2025-05-21",{"date":709,"type":32},"2025-03-01",{"date":711,"type":22},"2026-03",{"name":713,"class":39},"Medstar Health Research Institute"]